Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ScienceFlow is a venture capital organization based in Donostia, Guipúzcoa, Spain. Founded to support life science discoveries, the firm provides investment opportunities specifically in the biotechnology sector. ScienceFlow is dedicated to fostering innovation by investing in early-stage companies that are positioned to make significant impacts in their fields.
The firm currently operates with a team of partners and external advisors who possess advanced degrees in relevant scientific fields. This expertise allows ScienceFlow to navigate the complexities of the life sciences market effectively. The organization has a defined exit strategy of up to four years, focusing on early-stage investments in biotechnology companies located in prominent life sciences hubs across Europe.
ScienceFlow's commitment to the biotechnology sector is reflected in its portfolio, which includes companies developing therapeutics for neurodegenerative diseases, cancer, and ophthalmic diseases. The firm’s strategic approach emphasizes scientific diligence and addressing unmet needs in high-growth markets.
ScienceFlow focuses its investments on early-stage biotechnology companies, particularly those located in prominent life sciences hubs. The firm evaluates scientific research, intellectual property, and competitive technologies to identify opportunities that address unmet needs in high-growth markets. This consistent investment strategy is designed to support companies that are poised for significant advancements in their respective fields.
The firm invests across various stages, including pre-seed, seed, seed-plus, Series A, Series B, and beyond, up to Series F and growth equity. ScienceFlow's geographic focus is primarily on Europe, where it seeks to engage with companies that demonstrate strong scientific foundations and innovative approaches. The firm looks for founders who are committed to addressing critical challenges in biotechnology and who have a clear vision for their company's future.
ScienceFlow's defined exit strategy of a maximum of four years underscores its commitment to timely returns on investment, making it an attractive partner for startups in the biotechnology sector.
ScienceFlow's portfolio includes eight notable companies, each contributing to advancements in biotechnology:
This diverse portfolio reflects ScienceFlow's commitment to supporting innovative solutions in the life sciences sector, particularly in areas with significant unmet medical needs.
Carlos Alberdi: Partner at ScienceFlow, Carlos brings extensive experience in venture capital and biotechnology investments. His background includes roles in various biotech firms, focusing on strategic growth and innovation.
Xabi Fernández: Partner at ScienceFlow, Xabi has a strong track record in supporting early-stage biotech companies. His expertise lies in evaluating scientific research and market potential.
Iakes Ezkurdia, PhD: Partner at ScienceFlow, Iakes holds a PhD and specializes in scientific diligence and biotechnology investments. His academic background enhances the firm's evaluation processes.
Humberto Segura: Partner at ScienceFlow, Humberto has a diverse background in venture capital and life sciences, contributing to the firm's strategic investment decisions.
Mikel Iriondo: Partner at ScienceFlow, Mikel focuses on early-stage investments in biotechnology, leveraging his experience in the sector to guide portfolio companies.
Mayr Alcaine: Partner at ScienceFlow, Mayr brings expertise in scientific research and investment strategies, supporting the firm's mission to foster innovation in biotechnology.
Susana Zuñiga, PhD: External Advisor at ScienceFlow, Susana holds a PhD and provides insights into scientific research and biotechnology trends.
Tomás Sobrino, PhD: External Advisor at ScienceFlow, Tomás has a PhD and offers expertise in evaluating scientific technologies and market opportunities.
William S. Korinek, PhD: Scientific Team member at ScienceFlow, William contributes his scientific expertise to the firm's investment evaluations.
Stefano De Socio, PharmD, MBA: Scientific Team member at ScienceFlow, Stefano combines his pharmaceutical and business knowledge to support the firm's investment strategies.
Peter Choo, MD, DrPH, MBA: Scientific Team member at ScienceFlow, Peter brings a medical and public health perspective to the firm's evaluations and strategic decisions.
To pitch to ScienceFlow, founders should visit the official website at scienceflow.eu or email info@scienceflow.eu. It is advisable to include a comprehensive overview of the business model, scientific research, and market potential in the pitch deck.
While specific application forms or portals are not disclosed, providing detailed information about the technology and its impact on the biotechnology sector is essential. Founders can expect a response within a reasonable timeframe, although exact timelines are not specified.
As of 2024, ScienceFlow has made significant strides in the biotechnology sector, focusing on early-stage investments. The firm has expanded its portfolio to include companies like Nido Biosciences and Astrocyte Pharma, both of which are developing innovative therapeutics for neurodegenerative diseases.
In 2024, ScienceFlow also announced its investment in Inspirna, a clinical-stage biopharma company, which is developing cancer drugs inspired by RNA biology. This investment aligns with the firm's focus on addressing unmet needs in high-growth markets.
ScienceFlow continues to engage with emerging biotechnology companies, providing strategic guidance and support to help them navigate the complexities of the life sciences market.
What are ScienceFlow's investment criteria?
ScienceFlow invests in early-stage biotechnology companies that demonstrate strong scientific foundations and innovative approaches. The firm evaluates scientific research, intellectual property, and competitive technologies to identify opportunities that address unmet needs in high-growth markets.
How can I pitch to ScienceFlow?
Founders can pitch their companies by visiting the ScienceFlow website at scienceflow.eu or by emailing info@scienceflow.eu. It is recommended to provide a detailed overview of the business model, scientific research, and market potential in the pitch.
What makes ScienceFlow different from other venture capital firms?
ScienceFlow specializes in biotechnology investments and employs a rigorous evaluation process focused on scientific diligence. The firm’s team includes experts with advanced degrees in relevant scientific fields, providing strategic guidance and support to portfolio companies.
What is the geographic scope of ScienceFlow's investments?
ScienceFlow primarily focuses on early-stage biotechnology companies located in prominent life sciences hubs across Europe.
What is the typical check size for investments?
Specific check sizes are not disclosed, but ScienceFlow invests across various stages, including pre-seed, seed, and Series A through Series F, indicating a flexible investment approach.
What kind of support does ScienceFlow provide to portfolio companies?
ScienceFlow adds value through its deep expertise in scientific research and biotechnology, offering strategic guidance and support in navigating the complexities of the life sciences market.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.